Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

OTHER 1NETWORK 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Lymphoid 8Other hematologic neoplasm 6Myeloid 3Genitourinary 3Gastrointestinal 3Thoracic 2Plasma cell 2Dermatologic 2Breast 2Tumor-Agnostic 1Sarcoma 1Other solid neoplasm 1Head & Neck 1Classical hematology 1

Conditions

Breast Neoplasms 2

Interventions

Trastuzumab 260Paclitaxel 216Cyclophosphamide 173Docetaxel 146Letrozole 126Fulvestrant 121Capecitabine 121Doxorubicin 111Carboplatin 98Bevacizumab 90exemestane 88Anastrozole 85Tamoxifen 77Lapatinib 77pembrolizumab 68Albumin-Bound Paclitaxel 67pertuzumab 62palbociclib 60Taxes 59Gemcitabine 57eribulin 48130-nm albumin-bound paclitaxel 47Radiotherapy 46Everolimus 44Ado-Trastuzumab Emtansine 43Vinorelbine 39ixabepilone 32Epirubicin 30Cisplatin 30pegfilgrastim 29

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Has results × Amplified Fragment Length Polymorphism Analysis × Breast × Clear all
NCT00665457 2023-09-13

Biomarkers in Women Receiving Chemotherapy & Celecoxib for Stage II or Stage III Breast Cancer Removable by Surgery

University of Nebraska

Phase 2 Terminated
3 enrolled 6 charts
Breast

Breast Neoplasms

NCT01281137 2021-10-06

SOLE-EST

ETOP IBCSG Partners Foundation

Completed
104 enrolled 13 charts
Breast

Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡